X4A MARKETWIRE
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3…
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer | $BNTX HKEX: 9606.HK
CHART
$BNTX
Range
1 month
Chart loads when visible
Market data displayed by TradingView. Market data may be delayed.
SOURCE